The economic impacts of using adalimumab (Humira<sup>®</sup>) for reducing pain in people with ankylosing spondylitis: A microsimulation study for Australia

Schofield, Deborah; Shrestha, Rupendra; Cunich, Michelle

doi:10.1111/1756-185x.13277

Cited by 4 publications

(3 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Effective treatment can reduce disease severity, increase physical function and quality of life, improve work capacity and productivity, thus in return alleviating economic burden in the long term. Previous studies conducted in Europe (12) and Australia (22) showed decreased healthcare resource utilization and increased labor force participation rate after adalimumab therapy. In this study, improvement of work outcomes was observed after adalimumab treatment while no significant difference was found in total cost and indirect cost, indicating that it may take time to observe the long-term benefit.…”

Section: Discussionmentioning

confidence: 85%

Cost of Illness, Quality of Life, and Work Outcomes in Active Ankylosing Spondylitis Patients Treated With Adalimumab in China

Xie

Liao

et al. 2020

Front. Public Health

View full text Add to dashboard Cite

Objectives: To access the cost of illness, quality of life and work limitation in active ankylosing spondylitis (AS) patients using adalimumab in China.Methods: A prospective study was performed in 91 patients with active AS in China. Adult patients (aged ≥ 18 years) fulfilled the 1984 New York modified criteria of AS with the Bath Ankylosing Spondylitis Disease Activity Index ≥ 4 were enrolled. All participants received adalimumab (40 mg per 2 weeks) therapy and completed questionnaires about disease characteristics, quality of life and cost. Only patients with pay-work completed the Work Limitation Questionnaire and Work productivity and activity impairment questionnaire in AS. Factors associated with work outcomes were evaluated.Results: A total of 91 patients with mean age of 30 years old (87.8% males) and mean disease duration of 10 years received adalimumab treatment for 24 weeks. The annual estimated cost of each patient was $37581.41 while the direct cost accounted for 84.6%. Seventy-eight percent of patients have a paid job with average work productivity loss of 0.28 measured by work limitation questionnaire, absenteeism and presenteeism were 10.22 and 43.86%, respectively, with a mean work productivity loss of 47.92% measured by Work productivity and activity impairment questionnaire in AS. Patients experienced significantly greater improvements after adalimumab treatment in presenteeism, absenteeism, work productivity, and quality of life.Conclusions: The cost of AS patients with adalimumab therapy was high in China. Disease activity, physical function, quality of life, and work outcomes improved significantly after therapy.

show abstract

Section: Discussionmentioning

confidence: 85%

Cost of Illness, Quality of Life, and Work Outcomes in Active Ankylosing Spondylitis Patients Treated With Adalimumab in China

Xie

Liao

et al. 2020

Front. Public Health

View full text Add to dashboard Cite

show abstract

“…Twenty-three studies on costs of WP were cross-sectional or retrospective and therefore did not comply with inclusion criteria to assess general methodological choices. A total of 81 studies were included in our analysis (flowchart in online supplemental figure S2): 58 for extraction of general methodological choices,16–73 23 for outcome reporting studies on costs of work productivity16 74–96 and one providing information on both outcomes 16…”

Section: Resultsmentioning

confidence: 99%

Methodological aspects of design, analysis and reporting of studies with work participation as an outcome domain in patients with inflammatory arthritis: results of two systematic literature reviews informing EULAR points to consider

et al. 2021

View full text Add to dashboard Cite

ObjectiveTo summarise the methodological aspects in studies with work participation (WP) as outcome domain in inflammatory arthritis (IA) and other chronic diseases.MethodsTwo systematic literature reviews (SLRs) were conducted in key electronic databases (2014–2019): search 1 focused on longitudinal prospective studies in IA and search 2 on SLRs in other chronic diseases. Two reviewers independently identified eligible studies and extracted data covering pre-defined methodological areas.ResultsIn total, 58 studies in IA (22 randomised controlled trials, 36 longitudinal observational studies) and 24 SLRs in other chronic diseases were included. WP was the primary outcome in 26/58 (45%) studies. The methodological aspects least accounted for in IA studies were as follows (proportions of studies positively adhering to the topic are shown): aligning the studied population (16/58 (28%)) and sample size calculation (8/58 (14%)) with the work-related study objective; attribution of WP to overall health (28/58 (48%)); accounting for skewness of presenteeism/sick leave (10/52 (19%)); accounting for work-related contextual factors (25/58 (43%)); reporting attrition and its reasons (1/58 (2%)); reporting both aggregated results and proportions of individuals reaching predefined meaningful change or state (11/58 (16%)). SLRs in other chronic diseases confirmed heterogeneity and methodological flaws identified in IA studies without identifying new issues.ConclusionHigh methodological heterogeneity was observed in studies with WP as outcome domain. Consensus around various methodological aspects specific to WP studies is needed to improve quality of future studies. This review informs the EULAR Points to Consider for conducting and reporting studies with WP as an outcome in IA.

show abstract

“…Chronic pain commonly affects peoples' ability to perform day-to-day activities and limits their capacity to remain in paid employment. [7][8][9][10][11]43,49,56 Patients with chronic pain often also experience poor mental health, 45 such as heightened depression and anxiety symptoms. The costs of chronic pain place a significant public health burden on countries.…”

Section: Introductionmentioning

confidence: 99%

Economic analysis of patient-related effects of an interdisciplinary pain self-management program

Chowdhury

Schofield

Shrestha

et al. 2023

Pain

Self Cite

View full text Add to dashboard Cite

Active Day Patient Treatment (ADAPT) is a well-established 3 week intensive cognitive-behavioural, interdisciplinary pain management program for patients with disabling chronic pain. The aim of this analysis was to conduct an economic analysis of patient-related effects of ADAPT using hospital administrative data, specifically, to compare the costs and health outcomes for patients 1 month after participating in the program, with the preprogram period when they were receiving standard care. This retrospective cohort study included 230 patients who completed ADAPT (including follow-ups) between 2014 and 17 at the Pain Management and Research Centre at the Royal North Shore Hospital in Sydney, Australia. Data on pain-related healthcare utilization and costs before and after the program were assessed. Primary outcome measures were labour force participation for patients' average weekly earnings and cost per clinically meaningful change in Pain Self-efficacy Questionnaire, Brief Pain Inventory (BPI) Severity, and BPI interference scores (n = 224). We estimated patients, on average, earned $59 more each week at 1 month follow-up compared with baseline. The cost per clinically meaningful change in pain severity and interference score based on the BPI severity and BPI interference were AU$9452.32 (95% CI: $7031.76-$12,930.40) and AU$3446.62 (95% CI: $2851.67-$4126.46), respectively. The cost per point improvement and per clinically meaningful change in the Pain Self-efficacy Questionnaire were $483 (95% CI: $411.289-$568.606) and $3381.02, respectively. Our analysis showed a better health outcome, reduced healthcare services' cost, and reduced number of medications taken 1 month after participating in ADAPT.

show abstract

The economic impacts of using adalimumab (Humira^®) for reducing pain in people with ankylosing spondylitis: A microsimulation study for Australia

Abstract: Adalimumab therapy generates substantial economic benefits in addition to health benefits for individuals, and savings for government.

Cited by 4 publications

References 33 publications

Cost of Illness, Quality of Life, and Work Outcomes in Active Ankylosing Spondylitis Patients Treated With Adalimumab in China

Cost of Illness, Quality of Life, and Work Outcomes in Active Ankylosing Spondylitis Patients Treated With Adalimumab in China

Methodological aspects of design, analysis and reporting of studies with work participation as an outcome domain in patients with inflammatory arthritis: results of two systematic literature reviews informing EULAR points to consider

Economic analysis of patient-related effects of an interdisciplinary pain self-management program

Contact Info

Product

Resources

About

The economic impacts of using adalimumab (Humira®) for reducing pain in people with ankylosing spondylitis: A microsimulation study for Australia

Abstract: Adalimumab therapy generates substantial economic benefits in addition to health benefits for individuals, and savings for government.

Cited by 4 publications

References 33 publications

Cost of Illness, Quality of Life, and Work Outcomes in Active Ankylosing Spondylitis Patients Treated With Adalimumab in China

Cost of Illness, Quality of Life, and Work Outcomes in Active Ankylosing Spondylitis Patients Treated With Adalimumab in China

Methodological aspects of design, analysis and reporting of studies with work participation as an outcome domain in patients with inflammatory arthritis: results of two systematic literature reviews informing EULAR points to consider

Economic analysis of patient-related effects of an interdisciplinary pain self-management program

Contact Info

Product

Resources

About

The economic impacts of using adalimumab (Humira^®) for reducing pain in people with ankylosing spondylitis: A microsimulation study for Australia